Delivery Order SPE2DB22D3010-SPE2DB26FP0TF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) with a ceiling value of $9,967.07. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 8, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $2,927.61. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and represents a non-competitive set-aside award. The order will be performed at the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Rexulti 0.5 mg tablets in a 30-count package. This firm fixed-price delivery order, valued at $3,904.92, is scheduled for completion by September 10, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,846.60 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. The award was issued on September 23, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $5,123.39 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Rexulti 1 mg tablets (30-count units). The contract, which is a firm fixed price delivery order with no set-aside designation, is scheduled for completion by September 22, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Rexulti 2 mg tablets (30-count units) valued at $12,358.69. This is a firm fixed price, non-set-aside delivery order with a completion date of September 16, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's extensive role as a critical pharmaceutical supplier to the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $3,299.21. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 28, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $9,482.33. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on August 1, 2025, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB26FP0TFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) valued at $4,531.84. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for ultimate completion by October 27, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026. AmerisourceBergen serves as a major federal pharmaceutical distributor supporting military and veteran healthcare systems, with this IDC enabling the company to supply a comprehensive range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare customers worldwide. The current delivery order for Rexulti, an atypical antipsychotic medication, exemplifies the company's role in fulfilling routine pharmaceutical procurement needs within the military health system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 10/24/25 |